https://www.biopharmawatch.com/blog/biotech-stocks-hedge-funds-are-buying-q2-2026 BiopharmaWatch en 2026-08-30T22:41:03.361Z The 28 Biotech Stocks Hedge Funds Are Buying and Holding in 2026 (Q2 13F Special Report) https://www.biopharmawatch.com/news/ARWR/arrowhead-phase-3-shasta-3-4-plozasiran-results BiopharmaWatch en 2026-08-30T15:30:00.000Z Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia https://www.biopharmawatch.com/news/ALNY/alnylam-esc-congress-2026-data BiopharmaWatch en 2026-08-30T12:23:00.000Z Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings https://www.biopharmawatch.com/news/BMY/bmy-camzyos-long-term-efficacy-esc-congress-2026 BiopharmaWatch en 2026-08-29T15:00:00.000Z Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026 https://www.biopharmawatch.com/news/CYTK/cytokinetics-acacia-hcm-maple-hcm-results-esc-2026 BiopharmaWatch en 2026-08-29T14:30:00.000Z Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026 https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-phase-3-level-results-esc-congress-2026 BiopharmaWatch en 2026-08-29T12:21:00.000Z Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026